CD38 negative anaplastic plasma cell myeloma with (14;16) translocation: a diagnostic dilemma for highly aggressive neoplasm: case report
- 3 Downloads
Anaplastic plasma cell myeloma (PCM) is an aggressive morphological variant of myeloma characterized by involvement of extramedullary sites and extremely poor prognosis. Moreover, anaplastic PCM is frequently associated with high frequency of 17p(p53) deletions, 1q21(CKS1B) amplifications and immunoglobulin A (IgA) isotype. It usually manifests as an adverse progression of previously treated conventional plasma cell myeloma. However, the anaplastic morphology can be encountered in newly diagnosed cases and might pose a major diagnostic challenge. Herein, we present a rare case of anaplastic plasma cell myeloma with (14;16) translocation which was diagnosed initially as a non-hematopoietic malignancies due to its unusual clinicopathological profile comprising acute presentation, extremely anaplastic morphology, and negative staining of CD38 immunohistochemical marker. In view of lack of clinical suspicion of plasma cell myeloma, no serological investigations for myeloma had been requested initially. In fact, high index of suspicion of myeloma arose only when results of MRI and CT scan came out revealing bony lytic lesions and collapsed vertebrae. Subsequently, bone marrow biopsy was repeated and revealed an extensive infiltration with sheets of neoplastic plasma cells which were strongly positive for CD138, KAPPA, and CD56 IHC markers.
KeywordsAnaplastic myeloma CD38 IHC markers t(14;16)
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 4.Fujimi A, Nagamachi Y, Yamauchi N, Kanisawa Y (2017) Morphological transformation of myeloma cells into multilobated plasma cell nuclei within 7 days in a case of secondary plasma cell leukemia that finally transformed as anaplastic myeloma. Case Rep Hematol 2017:5758368PubMedPubMedCentralGoogle Scholar
- 8.Fedele G, Di Girolamo M, Recine U, Palazzo R, Urbani F, Horenstein AL et al (2013) CD38 ligation in peripheral blood mononuclear cells of myeloma patients induces release of protumorigenic IL-6 and impaired secretion of IFNgamma cytokines and proliferation. Mediat Inflamm 2013:564687CrossRefGoogle Scholar
- 13.Dingli D, Ailawadhi S, Bergsagel PL, Buadi FK, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves WI, Hayman SR, Kapoor P, Kourelis T, Kumar SK, Kyle RA, Lacy MQ, Leung N, Lin Y, Lust JA, Mikhael JR, Reeder CB, Roy V, Russell SJ, Sher T, Stewart AK, Warsame R, Zeldenrust SR, Rajkumar SV, Chanan Khan AA (2017) Therapy for relapsed multiple myeloma: guidelines from the Mayo stratification for myeloma and risk-adapted therapy. Mayo Clin Proc 92(4):578–598CrossRefGoogle Scholar
- 14.Avet-Loiseau H, Malard F, Campion L, Magrangeas F, Sebban C, Lioure B, Decaux O, Lamy T, Legros L, Fuzibet JG, Michallet M, Corront B, Lenain P, Hulin C, Mathiot C, Attal M, Facon T, Harousseau JL, Minvielle S, Moreau P, for the Intergroupe Francophone du Myelome (2011) Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood 117(6):2009–2011CrossRefGoogle Scholar
- 15.Nair B, van Rhee F, Shaughnessy JD Jr, Anaissie E, Szymonifka J, Hoering A et al (2010) Superior results of total therapy 3 (2003–33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006–66 with VRD maintenance. Blood 115(21):4168–4173CrossRefGoogle Scholar
- 16.Vega F, Chang C-C, Medeiros LJ, Udden MM, Cho-Vega JH, Lau C-C, et al (2005) Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. 806–15 pGoogle Scholar